Research and development of male contraceptives with good contraceptive effect without affecting sexual desire

Scientists at the University of Washington and UCLA believe that they have developed male contraceptives that are as safe and effective as female contraceptives.

Male contraceptives? Yes, you heard me right! At the endocrine conference of the Endocrine Society last Sunday, researchers reported the development of a drug called dimethandrolone undecanoate (DMAU), which is very similar to women’s daily contraceptives and has been proven in male subjects. Safe and effective.

100 adult volunteers aged 18 to 50 participated in clinical trials of the drug. The drugs are divided into three groups according to the dosage, and each group of drugs is divided into two groups according to different ingredients, which are wrapped in castor oil or powder. Five people in each dose group received a placebo. The trial lasted a month, and volunteers were asked to swallow a pill every day with mixed food-eventually 38 people completed the experiment.

At the end of the experiment, subjects taking DMAU underwent blood biochemical tests. The tests found that their testosterone and the other two hormones responsible for sperm production decreased, with the most significant decrease in the highest dose group. Because the experiment only lasted for one month, and in general, a significant decrease in sperm count could be detected under low hormonal environment for three consecutive months, so this experiment did not take sperm count as a direct indicator. However, existing studies have shown that the amount of hormones can be directly linked to infertility, and the decline in hormone levels in the maximum dose group is lower than the reference line, which can prove the effectiveness of the drug. It is worth mentioning that all subjects’ hormone levels returned to normal within one month after the drug was stopped.

Stephanie Page, the medical professor from the University of Washington, said at the annual meeting: “The acquisition of this compound is a major breakthrough for the development of male contraceptives, and we are glad to see that the experiment has achieved the expected results.” The University of Washington and the University of California, Los Angeles completed the collaboration.

Barriers to the birth of male contraceptives, and DMAU have been ambitious since its inception to try to overcome them. The one that has made the most progress before is a drug that combines progesterone with artificial testosterone. Progesterone can stop the testes from producing testosterone, which can further reduce spermatogenesis. Artificial testosterone is responsible for simulating and replacing other necessary functions of testosterone. Although the drug proved to be effective, it was left alone because it could not be taken orally.

All previous drugs that mimic testosterone must be taken at least twice a day because of their poor efficacy and side effects such as liver damage or mood changes. In 2016, a clinical trial of an artificial testosterone-injected drug was temporarily suspended due to the fact that multiple men reported severe emotional problems during the trial, and even one subject committed suicide while taking depression. (However, it should be noted that most of the participants indicated that they would continue to take the drug if it was marketed.)

So why did DMAU make a breakthrough? Its target of action is on the receptors of testosterone and progesterone. Compared with similar drugs, it is easier to be absorbed by tissues, and its effect is longer. This shows that one pill a day can exert contraceptive effects. Can cause adverse symptoms in the body. Page said: “For us, the biggest breakthrough is that the drug has no serious side effects, and the human body can tolerate the drug very well. There were no common oral symptoms such as vomiting, and we did not detect any liver damage. signal of.”

Other minor side effects observed by the Page team include weight gain and decreased HDL (a decrease in HDL helps reduce the risk of cardiovascular disease). But they think that these side effects can be solved by adjusting the dosage. Importantly, the drug will not produce any persistent symptoms after the drug is stopped, and testosterone levels will return to normal. But there is one side effect that could be of concern: Eight men in the test group reported a decline in their sexual desire. After stopping the drug, it returned to normal.

However, although this study provides a glimmer of hope, it is still a long way from the actual market introduction. Researchers are conducting a clinical trial for at least three months to prove whether the drug can reduce sperm. And then, tests between partners are needed to prove their actual contraceptive effect.

At the same time, there is another oral male contraceptive that has passed a phase of safety trial. The medicine is based on a different compound and also requires mixed food.

 Scientists at the University of Washington and UCLA believe that they have developed male contraceptives that are as safe and effective as female contraceptives.

Male contraceptives? Yes, you heard me right! At the endocrine conference of the Endocrine Society last Sunday, researchers reported the development of a drug called dimethandrolone undecanoate (DMAU), which is very similar to women’s daily contraceptives and has been proven in male subjects. Safe and effective.

100 adult volunteers aged 18 to 50 participated in clinical trials of the drug. The drugs are divided into three groups according to the dosage, and each group of drugs is divided into two groups according to different ingredients, which are wrapped in castor oil or powder. Five people in each dose group received a placebo. The trial lasted a month, and volunteers were asked to swallow a pill every day with mixed food-eventually 38 people completed the experiment.

At the end of the experiment, subjects taking DMAU underwent blood biochemical tests. The tests found that their testosterone and the other two hormones responsible for sperm production decreased, with the most significant decrease in the highest dose group. Because the experiment only lasted for one month, and in general, a significant decrease in sperm count could be detected under a low hormonal environment for three consecutive months, so this experiment did not take sperm count as a direct indicator. However, existing studies have shown that the number of hormones can be directly linked to infertility, and the decline in hormone levels in the maximum dose group is lower than the reference line, which can prove the effectiveness of the drug. It is worth mentioning that all subjects’ hormone levels returned to normal within one month after the drug was stopped.

Stephanie Page, the medical professor from the University of Washington, said at the annual meeting: “The acquisition of this compound is a major breakthrough for the development of male contraceptives, and we are glad to see that the experiment has achieved the expected results.” The University of Washington and the University of California, Los Angeles completed the collaboration.

Barriers to the birth of male contraceptives and DMAU have been ambitious since its inception to try to overcome them. The one that has made the most progress before is a drug that combines progesterone with artificial testosterone. Progesterone can stop the testes from producing testosterone, which can further reduce spermatogenesis. Artificial testosterone is responsible for simulating and replacing other necessary functions of testosterone. Although the drug proved to be effective, it was left alone because it could not be taken orally.

All previous drugs that mimic testosterone must be taken at least twice a day because of their poor efficacy and side effects such as liver damage or mood changes. In 2016, a clinical trial of an artificial testosterone-injected drug was temporarily suspended due to the fact that multiple men reported severe emotional problems during the trial, and even one subject committed suicide while taking depression. (However, it should be noted that most of the participants indicated that they would continue to take the drug if it was marketed.)

So why did DMAU make a breakthrough? Its target of action is on the receptors of testosterone and progesterone. Compared with similar drugs, it is easier to be absorbed by tissues, and its effect is more durable. Can cause adverse symptoms in the body. Page said: “For us, the biggest breakthrough is that the drug has no serious side effects, and the human body can tolerate the drug very well. There were no common oral symptoms such as vomiting, and we did not detect any liver damage. signal of.”

Other minor side effects observed by the Page team include weight gain and decreased HDL (a decrease in HDL helps reduce the risk of cardiovascular disease). But they think that these side effects can be solved by adjusting the dosage. Importantly, the drug will not produce any persistent symptoms after the drug is stopped, and testosterone levels will return to normal. But there is one side effect that could be of concern: Eight men in the test group reported a decline in their sexual desire. After stopping the drug, it returned to normal.

However, although this study provides a glimmer of hope, it is still a long way from the actual market introduction. Researchers are conducting a clinical trial for at least three months to prove whether the drug can reduce sperm. And then, tests between partners are needed to prove their actual contraceptive effect.

At the same time, there is another oral male contraceptive that has passed a phase of safety trial. The medicine is based on a different compound and also requires mixed food.

sex doll